EN DE
Watch Shandong Boan Biotech Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shandong Boan Biotech Co Ltd (6955) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Shandong Boan Biotech Co Ltd stock HK$0.46, price HK$3.03, that is 84.8% below the price, quality 29 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

SB Shandong Boan Biotech Co Ltd logo Thin data Nov 8, 2026

Shandong Boan Biotech Co Ltd

6955 · HK
Very expensive, weak quality

Our calculation puts a fair price 85% below what the stock costs today.

Low debt
Mixed Growth (revenue 3y +15.0 %/yr in CNY)
Loss over the last twelve months · -15.4% net margin (TTM) · fiscal year 2025 0.9%
Revenue last quarter 41% below a year ago.
Fair value HK$0.4600 · Strongly overvalued
Quality 29/100
Negative free cash flow
Trails peers (4/11)
Narrow moat 10/100 · thin data
Thin data
Watch Shandong Boan Biotech Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$24.55 HK$2.44 Fair Value HK$0.4600 Dec 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

46‑month range HK$2.44 – HK$24.55 · fair‑value band HK$0.3200 – HK$0.6000 · the HK$3.03 price screens above the HK$0.4600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Shandong Boan Biotech Co in your weekly email

Every Wednesday you see whether Shandong Boan Biotech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China.

Show moreShow less

The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal and male osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone.

It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit a; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial.

It has an agreement with the Zencore Biologics Co., Ltd. to use its stable cell line development platform non-exclusively, BA-HIEXcell for the development of antibodies and therapeutic proteins. The company was founded in 2013 and is headquartered in Yantai, China.

Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.

Stock analysis

Shandong Boan Biotech Co Ltd (6955) currently trades at HK$3.03, while our model-based Fair Value estimate is HK$0.4600, 85% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of HK$2.49 per share, and 1 of the 14 models we run sit above the HK$3.03 price.

Bear case: the Multiples group reads lowest at HK$0.4350, and 13 of the 14 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.3200 (bear) to HK$0.6000 (bull), the price of HK$3.03 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Shandong Boan Biotech Co Ltd reported revenue of 785M CNY in FY2025 versus 159M CNY in FY2021, a compound +49.1%/yr. Reported net income was 7.1M CNY in FY2025.

Key figures

Market cap HK$1.9B (≈ $241M) Micro · P/E ratio 471.0 · P/S ratio 4.29 · Net margin 0.9% · Return on equity −4.1% · Return on assets (EBIT) −4.9% (5-year average) · Operating margin −29.4% · Revenue (TTM) 624M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 73% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −85%, 6955 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (HK$0.2200 to HK$11.32). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear HK$0.3200 Fair Value HK$0.4600 Bull HK$0.6000
Price HK$3.03 · Downside -84.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
ROIC Compounder HK$2.08 HK$2.15 HK$2.20 72
EPV HK$2.08 HK$2.15 HK$2.20 71
Residual Income HK$2.60 HK$2.83 HK$3.21 71
All 14 models by family
Earnings-Based
Graham-Dodd HK$0.0900 HK$0.6500 HK$0.9100 63
Lynch FV HK$0.2500 HK$0.3600 HK$0.4700 61
PEG = 1.0 HK$0.2500 HK$0.3600 HK$0.4700 57
EPV HK$2.08 HK$2.15 HK$2.20 71
Multiples
P/E Multiple HK$0.2300 HK$0.3000 HK$0.3800 63
P/S Multiple HK$0.1700 HK$0.2300 HK$0.2900 58
P/B Multiple HK$8.49 HK$11.32 HK$14.15 55
EV/EBIT HK$0.2000 HK$0.5700 HK$0.9400 61
EV/EBITDA HK$1.76 HK$2.66 HK$3.55 66
EV/Revenue n/a HK$0.2200 HK$0.5600 50
Asset-Based
NCAV (Graham) HK$0.7900 HK$1.20 HK$1.50 54
Economic Profit
Residual Income HK$2.60 HK$2.83 HK$3.21 71
ROIC Compounder HK$2.08 HK$2.15 HK$2.20 72
Growth Earnings
Growth-Adj P/E HK$0.3200 HK$0.4600 HK$0.6000 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 16
How much profit the company makes from its sales and capital
Quality Growth 21
Are margins and returns getting better?
Cashflow 35
Do the profits arrive as real cash?
Financial strength 86
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 60
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 4
Distance to the 52-week high, does not count
New shares 45
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 42/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+8.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−134.7% (2021) → 5.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

6955 screens overvalued: fair value 85% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Shandong Boan Biotech Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −84.8% · Bottom 25%
Profitability
Return on assets 0.2% · Above median
Net margin (12 months) −15.4% · Below median
Operating margin (12 months) −29.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −40.8% · Bottom 25%
Balance sheet
Debt / equity 0.11× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 471.0× · Priciest 25%
P/B 0.59× · Cheapest 25%
P/S (12 months) 2.57× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)94 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6955
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6955
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6955
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 6955
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6955
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 6955
argenx SE ARGX $927.21 $908.40 −2% vs 6955
CSL Limited CSL A$200.77 A$183.04 −9% vs 6955
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 6955
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6955

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shandong Boan Biotech Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Shandong Boan Biotech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6955

Frequently asked questions

Is Shandong Boan Biotech Co Ltd (6955) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of HK$0.4600 versus a price of HK$3.03, about 85% lower (overvalued).
What is the fair value of 6955?
Our model-based fair value for Shandong Boan Biotech Co Ltd is HK$0.4600 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$3.03.
What is the quality score of 6955?
Shandong Boan Biotech Co Ltd has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shandong Boan Biotech Co Ltd (6955)?
Our model-based price target is the fair value of HK$0.4600 (as of Nov 8, 2026) from 14 valuation models. Cautious scenario HK$0.3200, optimistic scenario HK$0.6000. It is a calculation from audited fundamentals, not an analyst target.
What is the Shandong Boan Biotech Co Ltd stock forecast for 2026?
Our models put fair value at HK$0.4600, about 85% lower versus a price of HK$3.03 (overvalued). Cautious scenario HK$0.3200, optimistic scenario HK$0.6000. The calculation is refreshed regularly with new filings.
What is the revenue of Shandong Boan Biotech Co Ltd (6955)?
Shandong Boan Biotech Co Ltd reported trailing-twelve-month revenue of about 624M CNY (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Shandong Boan Biotech Co Ltd (6955)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shandong Boan Biotech Co Ltd it is HK$0.4600 per share (as of Nov 8, 2026), against a price of HK$3.03. It is the blended result of 14 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Shandong Boan Biotech Co Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 6955 trades above its calculated fair value: price HK$3.03, fair value HK$0.4600, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6955?
No. The price is what the market pays today (HK$3.03); the fair value is what the company's own numbers justify (HK$0.4600). For Shandong Boan Biotech Co Ltd the two are HK$2.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shandong Boan Biotech Co Ltd worth?
The market values Shandong Boan Biotech Co Ltd at about HK$1.9B (market capitalisation, as of Nov 8, 2026). Per share that is HK$3.03; our models calculate a fair value of HK$0.4600 per share.
What do the bullish and bearish scenarios say about 6955?
Our models span a range for Shandong Boan Biotech Co Ltd: cautious scenario HK$0.3200, base HK$0.4600, optimistic HK$0.6000 per share (as of Nov 8, 2026, price HK$3.03). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6955?
Shandong Boan Biotech Co Ltd trades at a price-to-earnings ratio of 471.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.4600 is built from several models across several years. Other multiples: P/B 0.6, P/S 2.6.
How solid is the balance sheet of Shandong Boan Biotech Co Ltd (6955)?
Balance-sheet figures for Shandong Boan Biotech Co Ltd (as of Nov 8, 2026): return on equity −4.1%, debt of 0.11 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 6955 from its 52-week high?
Shandong Boan Biotech Co Ltd trades at HK$3.03, about 73% below its 52-week high of HK$11.05 and 24% above the low of HK$2.44 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.4600 is for.
Which stocks are comparable to Shandong Boan Biotech Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shandong Boan Biotech Co Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price HK$3.03, calculated fair value HK$0.4600 (−85%), Quality Score 29/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6955 calculated?
We run Shandong Boan Biotech Co Ltd through 14 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$0.4600 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Shandong Boan Biotech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shandong Boan Biotech Co Ltd (6955)?
The closing price on Nov 6, 2026 was HK$3.03. Our model-based fair value is HK$0.4600, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shandong Boan Biotech Co Ltd right now?
The price sits above even our optimistic bull case (HK$0.6000). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.3200 to HK$0.6000) leaves room in how you read the outcome.

Key figures of Shandong Boan Biotech Co Ltd

How large is the market capitalisation of Shandong Boan Biotech Co Ltd (6955)?
The market capitalisation of Shandong Boan Biotech Co Ltd is HK$1.9B (≈ $241M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shandong Boan Biotech Co Ltd (6955)?
The price-to-sales ratio of Shandong Boan Biotech Co Ltd is 4.29 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Shandong Boan Biotech Co Ltd (6955)?
The net margin of Shandong Boan Biotech Co Ltd is 0.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shandong Boan Biotech Co Ltd (6955)?
The return on equity (ROE) of Shandong Boan Biotech Co Ltd is −4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shandong Boan Biotech Co Ltd (6955)?
On an EBIT basis the return on assets of Shandong Boan Biotech Co Ltd is −4.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shandong Boan Biotech Co Ltd (6955)?
The operating margin of Shandong Boan Biotech Co Ltd is −29.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shandong Boan Biotech Co Ltd (6955)?
Revenue at Shandong Boan Biotech Co Ltd is growing −40.8% versus a year earlier (3y avg +15.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Shandong Boan Biotech Co Ltd (6955)?
Earnings per share at Shandong Boan Biotech Co Ltd are growing −70.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Shandong Boan Biotech Co Ltd (6955) generate?
The free cash flow of Shandong Boan Biotech Co Ltd is −209M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shandong Boan Biotech Co Ltd (6955) carry?
The net debt of Shandong Boan Biotech Co Ltd is 480M CNY (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Shandong Boan Biotech Co Ltd in the live analysis

One click puts Shandong Boan Biotech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.